New hope for Tough-to-Treat breast cancer brain tumors
NCT ID NCT04965064
Summary
This study is testing whether a combination of two drugs, neratinib and capecitabine, can help control breast cancer that has spread to the brain. It is for patients whose cancer is officially classified as HER2-negative but shows signs of abnormal HER2 activity on a special test. The goal is to see if this treatment can help patients live longer and keep the brain tumors from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.